DEFINING OPTIMAL IMMUNOTHERAPIES FOR TYPE 1 DIABETES
DEFINING OPTIMAL IMMUNOTHERAPIES FOR TYPE 1 DIABETES
The Novartis Foundation

The Novartis Foundation was an international scientific and educational charity (known until September 1997 as the Ciba Foundation), having been established in 1947 by the CIBA company of Basle, which merged with Sandoz in 1996 to form Novartis.

The Foundation promoted the study and general knowledge of science and encouraged international co-operation in scientific research. To this end, it organized internationally acclaimed meetings (typically eight symposia and allied open meetings and 15–20 discussion meetings each year) as well as publishing eight books per year featuring the presented papers and discussions from the symposia.

The Novartis Foundation’s headquarters at 41 Portland Place, London W1B 1BN provided library facilities open to graduates in science and allied disciplines, and accommodation and meeting facilities to visiting scientists and their societies.

Towards the end of 2006, the Novartis Company undertook a review of the Foundation as a consequence of which the Foundation’s Trustees were informed that Company support for the Foundation would cease with effect from the end of February 2008. The Foundation’s Trustees decided that when the Foundation was dissolved, it would be taken over by the Academy of Medical Sciences. Accordingly, the Novartis Foundation and all its publications are now incorporated within The Academy of Medical Sciences.

The Academy of Medical Sciences

The Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are converted into healthcare benefits for society. Our Fellows are the UK’s leading medical scientists from hospitals and general practice, academia, industry and the public service.

The Academy seeks to play a pivotal role in determining the future of medical science in the UK, and the benefits that society will enjoy in years to come. We champion the UK’s strengths in medical science, promote careers and capacity building, encourage the implementation of new ideas and solutions – often through novel partnerships – and help to remove barriers to progress. For further information visit http://www.acmedsci.ac.uk
DEFINING OPTIMAL IMMUNOTHERAPIES FOR TYPE 1 DIABETES
Contents


Editors: Gregory Bock (Organizer) and Jamie Goode

This symposium is based on a proposal made by Matthias von Herrath and Jeffrey Bluestone

Matthias von Herrath  Chair’s introduction  1

Alan K. Foulis  Pancreatic pathology in type 1 diabetes in human  2
Discussion  13

Daniel Pipeleers, Peter In ‘t Veld, Miriam Pipeleers-Marichal and Frans Gorus  The β cell population in type 1 diabetes  19
Discussion  24

Peter Reifsnyder, William Schott, Darcy Pomerleau, Mark D. Lessard, Brian W. Soper and Edward H. Leiter  Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation  32
Discussion  46

Damien Bresson and Matthias von Herrath  Resuscitating adaptive Tregs with combination therapies?  50
Discussion  60

Thomas W. H. Kay, Nadine L. Dudek, Kate Graham, Eugene Estella, Eveline Angstetra, Mark D. McKenzie, Jan Allison and Helen E. Thomas  Cytotoxic T cell mechanisms of β cell destruction in non-obese diabetic mice  68
Discussion  78
Li Zhang, Roberto Gianani, Maki Nakayama, Edwin Liu, Masakazu Kobayashi, Erin Baschal, Liping Yu, Sunanda Babu, Abby Dawson, Kelly Johnson, Mohamed Jahromi, Theresa Aly, Pamela Fain, Jennifer Barker, Marian Rewers and George S. Eisenbarth
Type 1 diabetes: chronic progressive autoimmune disease 85
Discussion 94

Teodora Staeva  Current and past prevention and intervention trials in type 1 diabetes 99
Discussion 109

Mark Peakman  CD8 and cytotoxic T cells in type 1 diabetes 113
Discussion 119

General discussion I 122

General discussion II 126

Pere Santamaria  Genetic and therapeutic control of diabetogenic CD8+ T cells 130
Discussion 136

General discussion III 141

Frank Waldron-Lynch, Matthias von Herrath and Kevan C. Herold  Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of β cell mass 146
Discussion 155

Bart O. Roep  Immune markers of disease and therapeutic intervention in type 1 diabetes 159
Discussion 171

Silvia Gregori, Manuela Battaglia and Maria-Grazia Roncarolo Re-establishing immune tolerance in type 1 diabetes via regulatory T cells 174
Discussion 183
Participants

Mark Atkinson  Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, JHMHSC R2-228, 1600 SW Archer Rd, Gainesville, FL 32610-0275, USA

Ezio Bonifacio  DFG Center for Regenerative Therapies Dresden, TU Dresden, Tatzberg 47/49, 01307 Dresden, Germany

Damien Bresson  La Jolla Institute for Allergy and Immunology, Developmental Immunology-3, 9420 Athena Circle, La Jolla, CA 92037, USA

Peter Butler  UCLA, MED/ENDO, Larry L. Hillblom Islet Research Center, 900A Weyburn Place #A, Los Angeles, CA 90024-2852, USA

George S. Eisenbarth  Barbara Davis Center for Childhood Diabetes, Fitzsimons, Room 4102D, Health Sciences Center, 4200 E. Ninth Ave, Denver, CO 80262, USA

Richard Flavell  Sterling Professor of Immunobiology, Yale University School of Medicine, HHMI, 300 Cedar Street, Suite S569, P.O. Box 208011, New Haven, CT 06520-8011, USA

Alan K. Foulis  Department of Pathology, Royal Infirmary, Glasgow G4 0SF, UK

Silvia Gregori  San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Via Olgettina 58, 20132 Milan, Italy

David A. Hafler  Harvard Medical School, Brigham & Women’s Hospital, 77 Avenue Louis Pasteur, Boston, MA 02115, USA

Jason Hafler  Magdalene College, University of Cambridge, Cambridge CB3 0AG, UK

Kevan C. Herold  Yale School of Medicine, S-115B, 300 Cedar St, New Haven, CT 06520, USA
PARTICIPANTS

Richard A. Insel Juvenile Diabetes Research Foundation, 120 Wall Street, 19th Floor, New York, NY 10005-4001, USA

Thomas W. H. Kay St Vincent’s Institute, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia

Edward H. Leiter The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA

Andrew Lew The Walter & Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3050, Australia

Mark Peakman Department of Immunobiology, King’s College London, School of Medicine at Guy’s, King’s College & St Thomas’ Hospitals, 2nd Floor, New Guy’s House, Guy’s Hospital, London SE1 9RT, UK

Daniel Pipeleers JDRF Center for Beta Cell Therapy in Diabetes, Brussels Free University-VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium

Bart O. Roep E3-2, Immunohematologie en Bloedtransfusie, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands

Pere Santamaria Department of Microbiology and Infectious Diseases, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada

Teodora Staeva Juvenile Diabetes Research Foundation, 120 Wall Street, 19th Floor, New York, NY 10005-4001, USA

Tim Tree Department of Immunobiology, Programme of Infection and Immunity, King’s College School of Medicine, King’s College London, New Guy’s House, Guy’s Hospital, London SE1 9RT, UK

Matthias von Herrath (Chair) Department of Immune Regulation, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
Chair’s introduction

Matthias von Herrath

La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Diabetes is a disease where we still have many gaps in our knowledge. It is a special disease because we can’t access the organ very well, especially during the prediabetic phase in humans. Perhaps by linking animal studies with in vitro studies of human cells and then actual human studies we can close some of these gaps during this meeting. This pertains to both the basic pathogenesis of the disease as well as clinical translations.

There are many areas that are important to me in this field. I want to learn more about how the human disease actually comes together. I want to understand the kinetics. There are certain things that continue to puzzle me: I don’t understand how an immune-mediated disease is sustained for such a long time (in some cases the prediabetic phase can last more than seven years). How can it be that cells are continuously regenerated to attack islets in this chronic fashion? That a comparatively low-grade inflammatory immunological process can continue like this for several years puzzles me.

Understanding these types of kinetics will not only translate into understanding the pathogenesis, but also devising an optimal therapy: for example, we do not know for how long we would have to stop aggressive cells for in order to circumvent recurrence of disease. Does immunosuppressive or immune modulatory therapy have to be administered continuously, even if bystander regulation and other immunological control mechanisms that can be self-sustained by autoantigens are being invoked? Here we should discuss these issues, and others, for example with the question of the number of important autoantigens in type 1 diabetes: is there just one antigenic ‘driver’pathway? I would also like to see parallels made with other diseases, where applicable, and we have therefore invited speakers whose main expertise is in multiple sclerosis and other autoimmune disorders.

Retrospectively, this conference turned out to be a treat in many respects even for those who would consider themselves to be seasoned investigators in the pathogenesis of type 1 diabetes. We uncovered crucial ‘forgotten’ human data sets that should be revisited and expanded, we learned much more about the human aspects of type 1 diabetes pathogenesis which will be important to properly adjust current animal models, and we better comprehended crucial therapeutic and kinetic issues of the disease.
Pancreatic pathology in type 1 diabetes in human

Alan K. Foulis

Department of Pathology, Royal Infirmary, Glasgow G4 OSF, UK

Abstract. In type 1 autoimmune diabetes there is a selective destruction of insulin-secreting β cells. Around the time of clinical presentation, insulitis, a chronic inflammatory infiltrate of the islets affecting primarily insulin containing islets, is present in the majority of cases. The inflammatory infiltrate consists primarily of T lymphocytes; CD8 cells outnumber CD4 cells, there are fewer B lymphocytes and macrophages are relatively scarce. β cell death may involve the Fas apoptotic pathway since they have been shown to express Fas, infiltrating T lymphocytes express Fas-L and apoptotic β cells have been described. Hyperexpression of class I MHC by all the endocrine cells in many insulin-containing islets is a well recognized phenomenon, characteristic of the disease. It has been argued that this is an earlier event than insulitis within a given islet and appears to be due to secretion of interferon α by β cells within that islet. A recent study has found evidence of Coxsackie virus infection in β cells in three out of six pancreases of patients with recent-onset type 1 diabetes. Coxsackie viruses are known to induce interferon α secretion by β cells and this could initiate the sequence of events that culminates in their autoimmune destruction.


There are a number of different ways of obtaining pancreas specimens from patients with type 1 diabetes. Historically, the most common source was retrospective collections of autopsy pancreases from children who had died around the time of clinical diagnosis (Foulis et al 1986, Gepts 1965). The disadvantage of this approach was that there was usually a degree of autolysis in the tissues and the pancreas would almost certainly have been fixed in formalin and paraffin embedded. These factors and the lack of access to peripheral blood of the patient limited the range of possible studies on these pancreases.

A radical departure from this historical practice has been the approach of the group from Osaka. They performed laparoscopic pancreatic biopsies on patients who had been diagnosed with type 1 diabetes in the previous three months. A great range of tests has been done on this tissue and the results have been correlated with clinical findings. The disadvantage is that the biopsies were small
(20–30 mg) leading to a possible sampling problem. Thus the biopsies of three out of the first seven patients had no insulin-containing islets (Hanafusa et al 1990). While pancreatic biopsy has proven to be safe, no other research group has adopted this practice.

Finally, in the last 15 years a number of patients with recent-onset disease have died in intensive care units and permission has been given to remove organs for transplantation. The pancreas has thus been removed immediately after death, there has been no shortage of tissue and a full range of tests could be done (Dotta et al 2007).

**Insulits**

If the pancreas of a patient who has had type 1 diabetes for more than five years is studied, the great majority of islets will be seen to be insulin deficient. They consist of a normal number of the other hormone-secreting cells found in the islets of the pancreas (pancreatic polypeptide-secreting PP cells, glucagon-secreting A cells and somatostatin secreting D cells) (Foulis & Stewart 1984). There has thus been selective loss of the β cells. If the pancreas is studied at or within a year or two of clinical diagnosis, three types of islet are found (Gepts 1965, Foulis & Stewart 1984). Firstly, approximately 70% of the islets are insulin deficient (identical to those found in patients with prolonged disease). Secondly, there are islets containing β cells that are affected by insulitis (a chronic inflammatory infiltrate within the islet, Fig. 1) and, thirdly, there are insulin-containing islets which appear essentially normal. The finding that 18%

![FIG. 1. Insulitis. There is a predominantly lymphocytic infiltrate in this islet.](image-url)